manual-prevencion

MANUAL SEOM DE PREVENCIÓN Y DIAGNÓSTICO PRECOZ DEL CÁNCER 190 6. BIBLIOGRAFÍA 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 2. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720. 3. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15:e484-92. 4. Goggins WB, Wong G. Cancer among Asian Indians / Pakistanis living in the United States: low incidence and generally above overall survival. Cancer Causes Control 2009;20:635-43. 5. Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta- analysis. PLoS One 2011;6:e27130. 6. Goh CL. Eeles RA. Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. Recent Results Cancer Res 2014;202:9-26. 7. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res 2014;202:27-37. 8. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010;100:693-701. 9. Klein EA, Thompson IM Jr, Targen CM, Crowley JJ, Lucia MS, Goodman PJ et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Prostate Cancer Prevention Trial (SELECT). JAMA 2011;2306:1549-56. 10. Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of the combination vitamin-E, soy and selenium. J Clin Oncol 2011;29:2386-90. 11. Thompson IM, Goodman PJ, TangenCM, Lucia MS, Miller JG, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. 12. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202. 13. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR et al. 5-alpha-reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 2010;106:1444-51. 14. Schröder FH, Jugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Prostate cancer mortality et 11 years of follow-up. N Engl J Med 2012;366:981-90. 15. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al. Mortality results from the Göteborg randomized population-based prostate cancer screening trial. Lancet Oncol 2010;11:725-32. 16. Andriole GL, Crawford D, Grubb RL, Buys SS, Chia D, ChurchTR et al. Prostate cancer screening in the randomized prostate, lung, colorectal and ovarian cancer screening trial: mortality results after 13 years of follow up. J Natl Cancer Inst 2012;104:125-32. 17. Djulbegovic M, Beth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al. Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ 2010;341:c4543. 18. Lumen N, Fonteyne V, de Meerleert G, Ost P, Villeirs G, Mottrie A et al. Population screening for prostate cancer: an overview of available studies and meta-analysis. Int J Urol 2012;19:100-8. 19. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.